OBJECTIVEdRecent studies have reported hemoglobin A 1c (HbA 1c ) differences across ethnic groups that could limit its use in clinical practice. The authors of the A1C-Derived Average Glucose study have advocated to report HbA 1c in estimated average glucose (AG) equivalents. The aim of this study was to assess the relationships between HbA 1c and the mean of three 7-point self-monitored blood glucose (BG) profiles, and to assess whether estimated AG is an accurate measure of glycemia in different ethnic groups.
T
he results of hemoglobin A 1c (HbA 1c ) measurements are used to evaluate quality of glycemic control in individuals with diabetes mellitus (1) . However, several studies have reported that HbA 1c levels may be significantly higher in non-Caucasian patients with diabetes for a given blood glucose (BG) range (2) (3) (4) . It has become clear that HbA 1c levels not only depend on the long-term BG concentration (5-7) but also may be influenced by genetic factors (8) (9) (10) as well as environmental factors such as smoking and obesity (11) .
The authors of the A1C-Derived Average Glucose study proposed to translate HbA 1c into estimated average glucose (AG) equivalents for monitoring glycemic control (12) . They asserted that this could facilitate the patient's comprehension of the value of a given HbA 1c measurement and could be used instead of HbA 1c . However, the potential racial and ethnic differences in hemoglobin glycation (3) and the impact of hemoglobin variants and erythrocyte survival on the HbA 1c assay (13) suggest that estimated AG may be a biased estimate of mean self-monitored BG (SMBG), depending on the specific ethnic group.
The aims of the current study were to analyze in the participants of the DURABLE trial the relationships between HbA 1c and mean SMBG across different ethnic groups with type 2 diabetes and to compare HbA 1c -derived estimated AG with mean SMBG to determine whether estimated AG is an accurate measure of glycemia.
RESEARCH DESIGN AND
METHODSdThe DURABLE trial (assessing the durability of basal vs. Lispro Mix 75/25 insulin efficacy) was a global study with the primary objective of comparing the efficacy, safety, and durability of two starter insulin regimens in patients with type 2 diabetes (14) . It enrolled a large, diverse cohort of patients from five continents. The DURABLE trial was conducted in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice and the Declaration of Helsinki. All sites received approval from Institutional Review Boards, and all patients provided written informed consent. Men and women 30 to 80 years of age with type 2 diabetes and HbA 1c .7.0% (53 mmol/mol) with use of at least two oral BG-lowering agents (minimum dose 1,500 mg/day metformin, one-half maximum daily dose sulfonylurea, and/or either 30 mg/ day pioglitazone or 4 mg/day rosiglitazone) for at least 90 days immediately before the study were eligible for the study (14) . Patients were excluded if they had a history of long-term insulin therapy, BMI .45 kg/m 2 , recent history of severe hypoglycemic episodes, or history of significant renal, hepatic, hematologic (including hemoglobinopathy, hemolytic anemia, sickle cell anemia, and severe blood loss), oncologic, or cardiac disease. Serum creatinine screening was performed locally for all patients. Metformin-treated patients were excluded if serum creatinine was $124 mmol/L (1.4 mg/dL) for women and $133 mmol/L (1.5 mg/dL) for men. At study entry, patients self-reported ethnic origin based on the following categories: Caucasian (European, Mediterranean, Middle Eastern), African descent (black), East/Southeast Asian (Myanmarese, Chinese, Japanese, Korean, Mongolian, Vietnamese), Western Asian (Pakistani, Indian Subcontinent), Hispanic (Mexican-American, Mexico, Central and South America), and other (mixed racial parentage, American Indian, Inuit). Because of the heterogeneity of their backgrounds, the small group of 62 individuals reported as "other" is not included in this analysis. Figure 1 depicts the relationship between HbA 1c and mean SMBG for all participants in the different ethnic groups and the corresponding regression equations and resulting regression lines for the ethnic groups. Differences between the ethnic groups are the largest in the clinically relevant HbA 1c range of 7.0-9.0% (53-75 mmol/mol). In this range, as depicted in Table 2 , the level of HbA 1c is 0.2-0.5% (2-6 mmol/mol) higher in Asian, Hispanic, and African descent participants compared with Caucasian participants.
Measurements
The estimated AG levels, calculated from HbA 1c levels, are given in Table 1 . As expected from the HbA 1c values, estimated AG is significantly higher in Hispanic and Asians than in Caucasians. Figure 2 depicts the relationship between the estimated AG and the mean SMBG. When estimated AG is an accurate reflection of mean SMBG, we expect a 1:1 linear (12) , and the actual values of mean BG as derived from self-monitoring. In the A1C-Derived Average Glucose study report, estimated AG was calculated in 507 patients (.80% Caucasians) by combining weighted results obtained during a 3-month period from at least 2 days of continuous glucose monitoring performed four times, with seven-point daily BG monitoring performed at least 3 days per week (12) . Although there was a good correlation between HbA 1c and estimated AG (R 2 of 0.84 for the whole group), visual inspection of this relationship shows that an HbA 1c of, for instance, 7% (53 mmol/mol) was associated with estimated AG varying between 7.0 mmol/L (127 mg/dL) and 11 mmol/L (200 mg/dL). In the current study, we observed a clear discrepancy between estimated AG and actually measured mean BG levels. With BG levels #11.6 mmol/L (210 mg/dL), estimated AG was higher than the actual average mean BG. When mean BG levels were .11.6 mmol/L (210 mg/dL), estimated AG was significantly lower than the measured BG levels. Thus, estimated AG overestimated BG at lower glucose levels and underestimated mean BG at higher glucose levels. From these results, we conclude that calculation of estimated AG from HbA 1c with the current formula leads to inaccurate results.
HbA 1c levels are determined by several factors, as has been described in several recent articles. In addition to BG levels, age, sex, BMI, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, current smoking, and alcohol consumption are independent predictors of HbA 1c level (11) . The data presented in this report confirm previous articles in which it was described that persons of African descent have higher HbA 1c levels than Caucasian persons across the full spectrum of BG levels (17, 18) . Another study reported a 0.5% (6 mmol/mol) higher HbA 1c in Hispanics compared with Caucasians (2). The investigators concluded that these differences may be based on types of lifestyles, health care access and utilization, or socioeconomic factors, and also possibly on biological differences such as hemoglobin glycation or erythrocyte survival (2). However, there was insufficient data to compare HbA 1c levels stratified for glycemic control based on BG monitoring. Our present analyses clearly show a 0.32-0.41% (3-5 mmol/mol) absolute difference in HbA 1c between Hispanics and Caucasians for a given mean BG level ranging from 5.6 to 15.0 mmol/L (100-260 mg/dL; Table 2 ). This difference may be explained, in part, by genetic determinants. In the third National Health and Nutrition Examination Survey, it recently was shown that at many HbA 1c genetic loci there is substantial race-ethnic heterogeneity in risk allele frequencies (19) . For the clinical situation, these results imply that goals for HbA 1c need to be different according to ethnic background, and also that cutoff values for establishing the presence of type 2 diabetes are different according to ethnic background. For example, it recently was demonstrated that retinopathy prevalence begins to increase at a lower HbA 1c level in those of African descent than in Caucasians (18) . Thus, in studies in which intensive diabetes treatment has been applied, such as the ACCORD study, using the same HbA 1c as treatment target for people from different ethnic backgrounds may have created a higher risk of hypoglycemia for those of Asian, African, or Hispanic origin. In this respect, reassessment of the ACCORD study results (20) with special attention to the relationship between ethnic background and risk of hypoglycemia seems warranted. An interesting finding in this study was that compared with Caucasians, Asians had higher postprandial BG levels despite similar fasting and premeal BG levels. This finding may suggest that this postprandial increase is a specific feature of type 2 diabetes in Asians.
One limitation of our study is that the association of HbA 1c and BG has been based on a single HbA 1c determination and on mean BG levels assessed from only three 7-point SMBG profiles obtained within a period of 2 weeks. However, the DURABLE trial included patients with relatively stable glycemic control and also ensured that BG measurements could be compared among participants by using a single type of BG meter (Roche, Mannheim, Germany). It has been shown clearly that HbA 1c levels reflect average glycemia of the most recent 5 weeks (21). We have no data regarding the quality of BG self-monitoring by the participants, because many of the participants may have been taught this technique during the run-in phase of the DURABLE trial. However, clinical experience suggests that patients find these BG meters easy to understand and use. Finally, there is a large amount of scatter in the data (as depicted in Fig. 1 ), possibly as a result of biological variation or experimental/analytical error. However, this scatter was rather similar to the results presented by McCarter et al. (22) in type 1 diabetic individuals. Greater numbers would have allowed for more detailed subanalyses.
We conclude that ethnicity has a strong influence on the relationship between HbA 1c and mean BG levels obtained by self-monitoring. This background needs to be taken into consideration when assessing HbA 1c levels as part of evaluation of (quality of) diabetes treatment and for setting glycemic targets. Moreover, at mean BG levels ,11.6 mmol/L (210 mg/dL), estimated AG overestimates the actual average BG; at levels .11.6 mmol/L (210 mg/dL), estimated AG underestimates the true BG levels, which limits the use of estimated AG as an accurate marker of glycemia in clinical practice. This post hoc analysis of the relationship between BG and HbA 1c was investigator-initiated (B.H.R.W.). For this, no financial support was requested nor provided. All authors had authority over manuscript preparation and the decision to submit the manuscript for publication. The funding source had no role in the design, conduct, or reporting of this analysis or in the decision to submit the manuscript for publication. No other potential conflicts of interest relevant to this article were reported.
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